Thus, strategies and mechanisms for small molecules that target the p53 pathway, including activating wild-type p53 and temporal combination with mitotic inhibitor, are encouraged and supportive for developing new ways of anti-cancer drug application and therapy [5,6]. The gene discussed is TP53; the disease is cancer.